Literature DB >> 11431368

Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.

N J Beasley1, C C Wykoff, P H Watson, R Leek, H Turley, K Gatter, J Pastorek, G J Cox, P Ratcliffe, A L Harris.   

Abstract

Carbonic anhydrase IX (CA IX) is a transmembrane glycoprotein with an active extracellular enzyme site. We have shown previously that it was hypoxia inducible and may therefore be an endogenous marker of hypoxia. It is overexpressed in some tumors, particularly renal cell carcinoma. The aim of this study was to examine the expression and localization of CA IX in head and neck squamous cell carcinoma (HNSCC) and relate this to the location of tumor microvessels, angiogenesis, necrosis, and stage. Expression of CA IX was determined by immunoblotting in three HNSCC cell lines grown in normoxia and hypoxia (pO(2) 0.1%) and three paired tumor and normal tissue samples of HNSCC. Archived paraffin sections (79) of HNSCC were immunostained with antibodies to CA IX and CD34 to determine microvessel density (MVD). By double staining sections with CA IX and CD34, the distance between blood vessels and the start of CA IX expression and necrosis was calculated. CA IX was induced by hypoxia in all three HNSCC cell lines and overexpressed in HNSCC tumor tissue. Overexpression was localized to the perinecrotic area of the tumor on immunostaining, and the percentage area of the tumor expressing CA IX was significantly higher with more tumor necrosis (P = 0.001), a high MVD (P = 0.02), and advanced stage (P = 0.033) on univariate analysis and necrosis (P = 0.0003) and MVD (P = 0.0019) on multivariate analysis. The median distance between a blood vessel and the start of CA IX expression was 80 microm (range, 40-140 microm). CA IX is overexpressed in HNSCC because of hypoxia and is a potential biomarker for hypoxia in this tumor. Overexpression may help to maintain the intracellular pH, giving tumor cells a survival advantage and enhancing resistance to radiotherapy and chemotherapy. CA IX is a potential target for future therapy in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431368

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Authors:  Narges K Tafreshi; Mark C Lloyd; Joshua B Proemsey; Marilyn M Bui; Jongphil Kim; Robert J Gillies; David L Morse
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 3.  Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding.

Authors:  Vijay M Krishnamurthy; George K Kaufman; Adam R Urbach; Irina Gitlin; Katherine L Gudiksen; Douglas B Weibel; George M Whitesides
Journal:  Chem Rev       Date:  2008-03       Impact factor: 60.622

Review 4.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

5.  Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response.

Authors:  Twan van den Beucken; Marianne Koritzinsky; Hanneke Niessen; Ludwig Dubois; Kim Savelkouls; Hilda Mujcic; Barry Jutten; Juraj Kopacek; Sylvia Pastorekova; Albert J van der Kogel; Philippe Lambin; Willem Voncken; Kasper M A Rouschop; Bradly G Wouters
Journal:  J Biol Chem       Date:  2009-06-29       Impact factor: 5.157

6.  Inconsistent effects of acidosis on HIF-alpha protein and its target genes.

Authors:  Carsten Willam; Christina Warnecke; Jörg C Schefold; Jan Kügler; Petra Koehne; Ulrich Frei; Michael Wiesener; Kai-Uwe Eckardt
Journal:  Pflugers Arch       Date:  2005-10-06       Impact factor: 3.657

7.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

Review 8.  Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.

Authors:  Görkem Eskiizmir
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-09-01

9.  Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant.

Authors:  Yanping Wang; Xiang-Yang Wang; John R Subjeck; Hyung L Kim
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

10.  Regulation of hypoxia-inducible genes by ETS1 transcription factor.

Authors:  Konstantin Salnikow; Olga Aprelikova; Sergey Ivanov; Sean Tackett; Monika Kaczmarek; Aldona Karaczyn; Herman Yee; Kazimierz S Kasprzak; John Niederhuber
Journal:  Carcinogenesis       Date:  2008-04-01       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.